Esketamine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Esketamine: From Treatment-Resistant Depression to Neurotic Depression
One-Sentence Summary
Esketamine (Spravato®) is the S-enantiomer of ketamine, globally approved by the FDA and EMA for treatment-resistant depression (TRD) via intranasal administration, but not yet registered in Singapore. The TxGNN model predicts it may be effective for Neurotic Depression (persistent depressive disorder, ICD-10 F34.1) — a condition that substantially overlaps with TRD both clinically and neurobiologically, with the same rapid glutamatergic mechanism underpinning both indications. While no clinical trials have specifically enrolled neurotic depression patients, 20 publications including multiple Phase 3 RCTs (TRANSFORM series, SUSTAIN-1, ESCAPE-TRD) provide compelling indirect evidence supporting this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Treatment-resistant depression (TRD) — FDA/EMA approved globally; not registered in Singapore |
| Predicted New Indication | Neurotic Depression (Persistent Depressive Disorder, ICD-10 F34.1) |
| TxGNN Prediction Score | 97.83% |
| Evidence Level | L2 |
| Singapore Market Status | 未上市 (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data was not retrieved in this Evidence Pack. Based on well-established pharmacological knowledge, esketamine acts as a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist — the S-enantiomer of racemic ketamine, with approximately twice the receptor binding affinity. By blocking NMDA receptors in prefrontal cortical circuits, esketamine rapidly restores synaptic plasticity: BDNF (brain-derived neurotrophic factor) levels increase, mTOR signaling activates, and synaptogenesis resumes in circuits impaired by chronic stress and depression. This mechanism produces antidepressant effects within hours to days, contrasting with the 4–6 week onset of conventional SSRIs and SNRIs — a critical advantage for severely and chronically depressed patients.
Neurotic depression (ICD-10 F34.1, equivalent to persistent depressive disorder in DSM-5) and treatment-resistant depression are clinically intertwined. Patients with chronic, low-grade neurotic depression frequently accumulate multiple failed antidepressant trials over years, progressively meeting TRD criteria. The pivotal esketamine clinical trial program — comprising TRANSFORM-1, TRANSFORM-2, TRANSFORM-3 (elderly patients), SUSTAIN-1 (relapse prevention), and the landmark 2023 ESCAPE-TRD trial published in the New England Journal of Medicine — enrolled TRD populations whose clinical profiles closely mirror neurotic depression patients. Notably, the ESCAPE-TRD trial demonstrated esketamine superiority over quetiapine augmentation for sustained remission, establishing esketamine's distinct clinical value in this chronically depressed phenotype.
The evidence base is further reinforced by multiple independent meta-analyses and international expert consensus statements confirming rapid antidepressant efficacy with a manageable safety profile. The TxGNN model's 97.83% prediction score for neurotic depression reflects this deep neurobiological and clinical proximity. For patients with chronic low-mood disorders who have not responded to conventional pharmacotherapy, esketamine represents a mechanistically justified and evidence-adjacent treatment option.
Clinical Trial Evidence
Currently no clinical trials are specifically registered for neurotic depression with esketamine.
The pivotal evidence comes from the TRD indication, which shares substantial clinical overlap with neurotic depression. Key completed trials include the TRANSFORM series (NCT02418585, NCT02418572, NCT02422186), SUSTAIN-1 (NCT02588326), and ESCAPE-TRD (NCT03965000), collectively enrolling over 1,500 TRD patients across completion dates spanning 2017–2023.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37792613 | 2023 | Phase 3 RCT | N Engl J Med | ESCAPE-TRD: Esketamine nasal spray + SSRI/SNRI vs. quetiapine + SSRI/SNRI; esketamine achieved significantly higher sustained remission rates in TRD |
| 31109201 | 2019 | Phase 3 RCT | Am J Psychiatry | TRANSFORM-2: Flexibly dosed esketamine nasal spray + new antidepressant significantly improved MADRS vs. placebo spray + new antidepressant in TRD |
| 31166571 | 2019 | Phase 3 RCT | JAMA Psychiatry | SUSTAIN-1: Esketamine significantly extended time to relapse vs. placebo in TRD patients who achieved stable remission during induction |
| 40601310 | 2025 | Phase 3 RCT | JAMA Psychiatry | First RCT evaluating esketamine monotherapy (without concurrent oral antidepressant) for TRD; assesses standalone efficacy |
| 39876682 | 2025 | Meta-analysis | Am J Psychiatry | PRISMA systematic review and meta-analysis: intranasal esketamine effective for TRD and acute suicidal ideation; comprehensive risk-benefit analysis across all major RCTs |
| 33022440 | 2021 | Meta-analysis | J Affect Disord | Comparative meta-analysis of racemic ketamine vs. esketamine for depression; both show rapid antidepressant effects; esketamine efficacy and safety confirmed |
| 33726522 | 2021 | Systematic Review | Am J Psychiatry | International expert consensus synthesizing evidence for ketamine/esketamine in TRD; practical implementation guidance with monitoring protocols |
| 35416105 | 2022 | Safety Review | Expert Opin Drug Saf | Long-term safety of ketamine/esketamine in depression: dissociative symptoms, hemodynamic changes, and abuse/misuse potential characterized with monitoring recommendations |
| 37149345 | 2023 | Review | Psychiatr Clin North Am | Pharmacotherapy overview: FDA/EMA-approved intranasal esketamine for TRD; dosing schedule, maintenance strategy, repeated administration, and adverse effect management |
| 39613748 | 2024 | Review | Transl Psychiatry | Personalized use of ketamine/esketamine for TRD: clinical and biological predictors of response to guide individualized treatment decisions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 RCTs — including the 2023 NEJM ESCAPE-TRD trial showing superiority over quetiapine — provide robust evidence for esketamine in TRD populations that substantially overlap with neurotic depression; the FDA and EMA approvals establish regulatory precedent and a well-characterized safety profile that supports careful clinical application in this adjacent indication.
To proceed, the following is needed:
- HSA Singapore registration application (no current market authorization; special import currently required for any access)
- Full prescribing information and TFDA package insert review to capture contraindications and boxed warnings (DG001 blocking data gap must be resolved before clinical deployment)
- Drug-drug interaction data collection (DDI gap currently unresolved)
- REMS-equivalent risk management protocol for controlled substance administration in the Singapore healthcare setting (onsite observation for ≥2 hours post-dose is standard international practice)
- Prospective observational study or dedicated RCT specifically enrolling neurotic depression (ICD-10 F34.1) patients to formally establish efficacy in this distinct subpopulation beyond TRD
- Health technology assessment and reimbursement feasibility review (Spravato® unit cost is a known access barrier in all markets)
Additional Noteworthy Predictions (This Evidence Pack)
This is a multi-indication evaluation (candidate ID: TW-DB11823-multi). Beyond neurotic depression, two further predictions warrant attention:
| Rank | Disease | Evidence Level | Recommendation | Key Highlight | |------|---------|--------------|----------------|---------------| | 4 | Melancholia | L2 | Proceed with Guardrails | Severe depressive subtype (DSM-5 specifier); same TRD evidence base applies; esketamine's rapid synaptic mechanism is especially well-suited to this treatment-refractory, anhedonic phenotype | | 6 | Obsessive-Compulsive Disorder (OCD) | L3 | Research Question | Glutamate dysregulation supports NMDA antagonist rationale; 6 trials identified including 1 prospective OCD-specific trial (NCT05577585, recruiting); retrospective chart review (PMID 38194244) shows initial efficacy signal | | 8 | Insomnia | L3 | Research Question | 46 trials identified; most with sleep as secondary endpoint; 2025 pilot study (PMID 40732353) shows esketamine add-on therapy reduces insomnia severity in TRD patients; dedicated primary insomnia RCT has not yet been completed |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.